BioCentury | Oct 10, 2016
Emerging Company Profile

Pellino play

...Seonghee Park University collaborators: Korea Research Institute of Chemical Technology , Sungkyunkwan University Corporate partners: BioLeaders Corp....
BioCentury | Apr 15, 2013
Company News

AnGes, BioLeaders, GenoLac deal

...vaccine targets the E7 transforming protein (Human papillomavirus-16; HpV16gp1) and uses Lactobacillus display technology from BioLeaders...
...be reached for details (see BioCentury, Aug. 15, 2011). AnGes MG Inc. (Tokyo:4563), Osaka, Japan BioLeaders Corp....
BioCentury | Apr 16, 2012
Company News

AnGes, BioLeaders deal

...vaccine technology from Osaka University. Details were not disclosed. AnGes MG Inc. (Tokyo:4563), Osaka, Japan BioLeaders Corp....
BioCentury | Apr 13, 2012
Company News

AnGes, BioLeaders to develop oral hypertension vaccine

...AnGes MG Inc. (Tokyo:4563) and BioLeaders Corp. Co. Ltd. (Daejeon, South Korea) partnered to develop an oral...
BioCentury | Nov 17, 2003
Strategy

Merger ups & downs

Restructuring in Germany is slowly progressing, with companies retooling, spinning out, selling assets and merging. But while one new merger was announced last week, another fell apart - illustrating how difficult it often is to put...
BioCentury | Nov 17, 2003
Company News

Biofrontera Pharmaceuticals Holding AG, Kiadis BV deal

Neurology company Biofrontera and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis (see BioCentury, Feb. 17). In July, however, Biofrontera...
BioCentury | Nov 14, 2003
Company News

Biofrontera, Kiadis call off merger

Neurology play Biofrontera (Leverkusen, Germany) and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis ( see BioCentury, Feb. 17, 2003 )....
BioCentury | Jul 21, 2003
Strategy

Biofrontera’s chemical attraction

When neurological company Biofrontera Pharmaceuticals Holding AG announced plans to merge with Kiadis B.V. , the attraction of Kiadis was its chemistry and screening technology, which Biofrontera said would help it develop compounds more rapidly. That...
BioCentury | Jul 21, 2003
Company News

Biofrontera Pharmaceuticals Holding AG, bioLeads deal

Biofrontera acquired all the assets of drug discovery company bioLeads, which became insolvent in March. Biofrontera will put the assets, including a library of two million natural compound fractions and a synthetic chemistry unit, into...
BioCentury | Jul 15, 2003
Company News

Biofrontera to acquire bioLeads assets

Neurological company Biofrontera (Leverkusen, Germany) acquired all the assets of drug discovery company bioLeads (Heidelberg, Germany), which became insolvent in March. Biofrontera will incorporate all of bioLeads' assets, including a library of two million natural...
Items per page:
1 - 10 of 15
BioCentury | Oct 10, 2016
Emerging Company Profile

Pellino play

...Seonghee Park University collaborators: Korea Research Institute of Chemical Technology , Sungkyunkwan University Corporate partners: BioLeaders Corp....
BioCentury | Apr 15, 2013
Company News

AnGes, BioLeaders, GenoLac deal

...vaccine targets the E7 transforming protein (Human papillomavirus-16; HpV16gp1) and uses Lactobacillus display technology from BioLeaders...
...be reached for details (see BioCentury, Aug. 15, 2011). AnGes MG Inc. (Tokyo:4563), Osaka, Japan BioLeaders Corp....
BioCentury | Apr 16, 2012
Company News

AnGes, BioLeaders deal

...vaccine technology from Osaka University. Details were not disclosed. AnGes MG Inc. (Tokyo:4563), Osaka, Japan BioLeaders Corp....
BioCentury | Apr 13, 2012
Company News

AnGes, BioLeaders to develop oral hypertension vaccine

...AnGes MG Inc. (Tokyo:4563) and BioLeaders Corp. Co. Ltd. (Daejeon, South Korea) partnered to develop an oral...
BioCentury | Nov 17, 2003
Strategy

Merger ups & downs

Restructuring in Germany is slowly progressing, with companies retooling, spinning out, selling assets and merging. But while one new merger was announced last week, another fell apart - illustrating how difficult it often is to put...
BioCentury | Nov 17, 2003
Company News

Biofrontera Pharmaceuticals Holding AG, Kiadis BV deal

Neurology company Biofrontera and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis (see BioCentury, Feb. 17). In July, however, Biofrontera...
BioCentury | Nov 14, 2003
Company News

Biofrontera, Kiadis call off merger

Neurology play Biofrontera (Leverkusen, Germany) and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis ( see BioCentury, Feb. 17, 2003 )....
BioCentury | Jul 21, 2003
Strategy

Biofrontera’s chemical attraction

When neurological company Biofrontera Pharmaceuticals Holding AG announced plans to merge with Kiadis B.V. , the attraction of Kiadis was its chemistry and screening technology, which Biofrontera said would help it develop compounds more rapidly. That...
BioCentury | Jul 21, 2003
Company News

Biofrontera Pharmaceuticals Holding AG, bioLeads deal

Biofrontera acquired all the assets of drug discovery company bioLeads, which became insolvent in March. Biofrontera will put the assets, including a library of two million natural compound fractions and a synthetic chemistry unit, into...
BioCentury | Jul 15, 2003
Company News

Biofrontera to acquire bioLeads assets

Neurological company Biofrontera (Leverkusen, Germany) acquired all the assets of drug discovery company bioLeads (Heidelberg, Germany), which became insolvent in March. Biofrontera will incorporate all of bioLeads' assets, including a library of two million natural...
Items per page:
1 - 10 of 15